ニュース

The organization warns that tariff uncertainty continues to negatively impact business confidence and investment.
Boehringer Ingelheim & Click Therapeutics’ phase III CONVOKE study of CT-155 for negative symptoms in schizophrenia meets primary endpoint: Ingelheim, Germany Saturday, August 9 ...